Ro7845860

Phase 1

Roche

Ro7845860 is one of 9 therapeutic programs targeting Relapsing Multiple Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Relapsing Multiple SclerosisNot yet recruiting

Relapsing Multiple SclerosisPhase 1

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Relapsing Multiple Sclerosis

#DrugCompanyPhaseTrials

Ocrevus

Roche

Approved

3 2

Rhapsido

Novartis

Phase 3

3 3

BRIUMVI

TTG Therapeutics, Inc.

Phase 3

4 4

Best Available Therapy

Novartis

Phase 3

1 5

Tolebrutinib

Sanofi

Phase 3

1 6

Fenebrutinib

Roche

Phase 3

4 7

Gilenya

Novartis

Preclinical

1 8

Rapcabtagene Autoleucel

Novartis

Preclinical

1 9

Ro7845860

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Not yet recruiting

Relapsing Multiple Sclerosis

NCT07749157

Clinical

Trials by Indication[1]

Relapsing Multiple Sclerosis1 trial

An Open-Label, Multicenter, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

Not yet recruiting· Roche logo

Roche·Phase 1·NCT07749157·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ro7845860. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ro7845860. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Roche

Ro7845860

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Relapsing Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News